Clinical Trial Update: High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating high-dose Firmonertinib with Bevacizumab and intrathecal Pemetrexed for EGFR-mutated non-small cell lung cancer with leptomeni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Firmonertinib (firmonertinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Qiming Wang | Conditions: Non Small Cell Lung Cancer, EGFR Mutation | Phase 2 | Status: NOT_YET_RECRUITING